tiprankstipranks
Trending News
More News >
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Advertisement

Cellectar Biosciences (CLRB) AI Stock Analysis

Compare
1,428 Followers

Top Page

CLRB

Cellectar Biosciences

(NASDAQ:CLRB)

Rating:34Underperform
Price Target:
Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company's valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.
Positive Factors
Regulatory Approval
Cellectar recently held a meeting with the FDA, which confirmed a clear path to accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia.
Strategic Partnerships
Cellectar remains in active discussions with potential partners to out-license Iopofosine-131 in Waldenstrom’s macroglobulinemia (WM).
Negative Factors
Financial Performance
Cellectar reported 2Q25 results with a net loss of ($5.4M) and ended the period with $11.0M in cash.
Program Development Uncertainty
Cellectar's radiopharma pipeline, including the P1-ready assets CLR-121225 and CLR-121125, were the key drivers for CLRB. As the company now seeks strategic alternatives for its assets, there is significant uncertainty regarding the future development of these programs.

Cellectar Biosciences (CLRB) vs. SPDR S&P 500 ETF (SPY)

Cellectar Biosciences Business Overview & Revenue Model

Company DescriptionCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
How the Company Makes MoneyCellectar Biosciences makes money primarily through the development and commercialization of its targeted cancer therapies. The company's revenue model is largely dependent on the successful advancement of its drug candidates through clinical trials and eventual approval by regulatory bodies. Additionally, Cellectar may generate revenue through partnerships, licensing agreements, and collaborations with larger pharmaceutical companies, enabling shared development costs and promotional activities. These partnerships can provide upfront payments, milestone payments, and royalties on sales upon successful commercialization of their therapies.

Cellectar Biosciences Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Neutral
The call highlighted significant progress in regulatory strategies and product pipeline advancements, especially with the potential accelerated approval path for Iopofosine I-131. However, the notable decrease in R&D and administrative expenses and an increased net loss indicate financial challenges. Overall, the sentiment is cautiously optimistic but tempered by financial concerns.
Q2-2025 Updates
Positive Updates
Regulatory Strategy for Iopofosine I-131
Cellectar plans to submit a New Drug Application (NDA) under an accelerated approval pathway for Iopofosine I-131 as a treatment for Waldenstrom's Macroglobulinemia (WM) with FDA breakthrough therapy designation and PRIME designation in Europe.
Financial Position and Funding
Cellectar raised nearly $10 million through recent financings and ended the quarter with $11 million in cash, adequate to fund operations into the second quarter of 2026.
Progress in Radiopharmaceutical Pipeline
Cellectar is on track to initiate Phase I trials for CLR 125 and CLR 225, targeting triple-negative breast cancer and solid tumors such as pancreatic cancer, respectively.
Negative Updates
Decreased R&D and Administrative Spending
Research and development expenses decreased significantly from $7.3 million to $2.4 million, and general and administrative expenses decreased from $6.4 million to $3.6 million, primarily due to reduced personnel costs and pre-commercialization efforts.
Significant Net Loss
Cellectar reported a net loss of $5.4 million for the quarter compared to $0.9 million in the same period the previous year, largely attributed to non-cash changes related to warrants.
Company Guidance
During the Cellectar Biosciences Second Quarter 2025 Financial Results and Business Update Conference Call, the company provided guidance on several key metrics. Cellectar plans to submit a New Drug Application (NDA) for iopofosine I-131 under an accelerated approval pathway with the FDA, contingent on sufficient funding and a confirmatory study being underway. The company has been granted breakthrough therapy designation by the FDA and prime designation by the EMA for this treatment. Financially, Cellectar ended the quarter with $11 million in cash, following a recent $5.8 million fundraise, and expects this to support operations into the second quarter of 2026. Research and development expenses decreased to $2.4 million from $7.3 million year-over-year due to the conclusion of patient enrollment and follow-up for the CLOVER-WaM Phase II study. The company reported a net loss of $5.4 million, impacted by noncash warrant activities. They anticipate rapid study enrollment for the confirmatory trial and are poised to advance their radiopharmaceutical pipeline, including CLR 125 and CLR 225, pending further funding.

Cellectar Biosciences Financial Statement Overview

Summary
Cellectar Biosciences is in a challenging financial position with zero revenue generation and continuous operational losses. The company heavily relies on external financing for cash flow needs, and its balance sheet shows vulnerabilities with negative or fluctuating equity. The consistent lack of revenue and profitability raises significant concerns about its financial sustainability.
Income Statement
10
Very Negative
Cellectar Biosciences has consistently reported zero revenue over the years, indicating a lack of commercialized products. The company operates at a loss, with significant negative net income each year. The EBIT and EBITDA margins are negative, reflecting operational challenges and lack of profitability.
Balance Sheet
25
Negative
The company exhibits a high dependency on equity financing, as seen in fluctuating stockholder's equity and negative equity in 2023. The debt-to-equity ratio is low, indicating limited use of debt, but the overall financial position is weak due to ongoing losses and negative equity in recent years.
Cash Flow
30
Negative
Cellectar Biosciences shows recurring negative free cash flow, indicating insufficient cash generation from operations. The company relies on financing activities to sustain operations, as evidenced by large financing cash inflows. Operating cash flow has been consistently negative, reflecting operational inefficiencies.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00
EBITDA-38.26M-51.49M-38.77M-28.67M-23.98M-14.89M
Net Income-29.07M-44.58M-42.77M-31.79M-24.12M-15.09M
Balance Sheet
Total Assets13.70M25.47M12.08M21.59M37.20M58.66M
Cash, Cash Equivalents and Short-Term Investments11.04M23.29M9.56M19.87M35.70M57.17M
Total Debt453.51K494.00K552.98K603.83K301.74K421.64K
Total Liabilities6.23M11.18M25.85M12.05M4.16M3.86M
Stockholders Equity7.47M14.29M-13.78M9.54M33.05M54.79M
Cash Flow
Free Cash Flow-34.64M-47.69M-33.24M-25.45M-22.71M-14.00M
Operating Cash Flow-34.58M-47.58M-32.38M-25.22M-22.57M-13.93M
Investing Cash Flow-61.29K-104.19K-864.04K-225.97K-141.36K-62.35K
Financing Cash Flow19.81M61.41M22.94M9.61M1.25M60.55M

Cellectar Biosciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.82
Price Trends
50DMA
5.22
Negative
100DMA
7.05
Negative
200DMA
11.89
Negative
Market Momentum
MACD
-0.16
Negative
RSI
48.14
Neutral
STOCH
57.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLRB, the sentiment is Positive. The current price of 4.82 is above the 20-day moving average (MA) of 4.65, below the 50-day MA of 5.22, and below the 200-day MA of 11.89, indicating a neutral trend. The MACD of -0.16 indicates Negative momentum. The RSI at 48.14 is Neutral, neither overbought nor oversold. The STOCH value of 57.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLRB.

Cellectar Biosciences Risk Analysis

Cellectar Biosciences disclosed 41 risk factors in its most recent earnings report. Cellectar Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cellectar Biosciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.33-41.57%2.23%23.26%-2.03%
49
Neutral
$103.54M-146.92%-61.16%-139.15%
48
Neutral
$16.41M-194.84%48.91%
40
Underperform
$14.09M-122.28%
34
Underperform
$15.55M-273.88%73.37%
34
Underperform
$16.50M1.59>-0.01%
31
Underperform
$11.95M-183.72%20.28%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLRB
Cellectar Biosciences
4.82
-59.38
-92.49%
CANF
Can-Fite BioPharma
0.66
-1.68
-71.79%
NERV
Minerva Neurosciences
2.26
-0.36
-13.74%
PRTG
Portage Biotech Inc
6.96
3.15
82.68%
LPTX
Leap Therapeutics
0.29
-2.62
-90.03%
EQ
Equillium
1.72
0.75
77.32%

Cellectar Biosciences Corporate Events

Executive/Board ChangesRegulatory Filings and Compliance
Cellectar Biosciences Enhances CEO and COO Severance Benefits
Neutral
Mar 17, 2025

On March 12, 2025, Cellectar Biosciences’ board approved amendments to the employment agreements of its CEO and COO, enhancing their severance benefits in the event of a change in control. Additionally, on March 11, 2025, the board adopted new by-laws to align with Delaware law, revising stockholder nomination procedures and reducing the quorum requirement for meetings.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025